Gene therapy for fanconi anemia.

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Fanconi anemia is a hereditary syndrome of bone marrow failure, congenital anomalies, and a predisposition to malignancy. Most patients die from bone marrow failure. Cells from patients display a heightened sensitivity to DNA cross-linking agents with increased chromosomal breakage and increased cytotoxicity. Bone marrow from patients with Fanconi anemia have decreased numbers of hematopoietic progenitors when grown in culture. Transfer of the normal Fanconi anemia cDNA into cells from patients corrects the laboratory abnormalities, suggesting that gene transfer may prevent or reverse the bone marrow failure. Advances in gene transfer into human hematopoietic cells make this approach seem feasible. However, decreased numbers of stem cell targets may represent a significant obstacle. In addition, new insights on potential toxicities related to gene transfer have heightened a cautious approach. Fanconi anemia represents a prototype disorder for gene therapy and highlights the difficulties in adapting this technology to human disease.

Original languageEnglish
Pages (from-to)335-340
Number of pages6
JournalCurrent hematology reports
Volume2
Issue number4
StatePublished - Jul 2003

Fingerprint

Fanconi Anemia
Genetic Therapy
Bone Marrow
Genes
Chromosome Breakage
Stem Cells
Complementary DNA
Technology
DNA
Neoplasms

ASJC Scopus subject areas

  • Hematology

Cite this

Gene therapy for fanconi anemia. / Croop, James.

In: Current hematology reports, Vol. 2, No. 4, 07.2003, p. 335-340.

Research output: Contribution to journalArticle

@article{2643ff5793ef471c981166887ef8afc4,
title = "Gene therapy for fanconi anemia.",
abstract = "Fanconi anemia is a hereditary syndrome of bone marrow failure, congenital anomalies, and a predisposition to malignancy. Most patients die from bone marrow failure. Cells from patients display a heightened sensitivity to DNA cross-linking agents with increased chromosomal breakage and increased cytotoxicity. Bone marrow from patients with Fanconi anemia have decreased numbers of hematopoietic progenitors when grown in culture. Transfer of the normal Fanconi anemia cDNA into cells from patients corrects the laboratory abnormalities, suggesting that gene transfer may prevent or reverse the bone marrow failure. Advances in gene transfer into human hematopoietic cells make this approach seem feasible. However, decreased numbers of stem cell targets may represent a significant obstacle. In addition, new insights on potential toxicities related to gene transfer have heightened a cautious approach. Fanconi anemia represents a prototype disorder for gene therapy and highlights the difficulties in adapting this technology to human disease.",
author = "James Croop",
year = "2003",
month = "7",
language = "English",
volume = "2",
pages = "335--340",
journal = "Current hematology reports",
issn = "1540-3408",
publisher = "Current Science, Inc.",
number = "4",

}

TY - JOUR

T1 - Gene therapy for fanconi anemia.

AU - Croop, James

PY - 2003/7

Y1 - 2003/7

N2 - Fanconi anemia is a hereditary syndrome of bone marrow failure, congenital anomalies, and a predisposition to malignancy. Most patients die from bone marrow failure. Cells from patients display a heightened sensitivity to DNA cross-linking agents with increased chromosomal breakage and increased cytotoxicity. Bone marrow from patients with Fanconi anemia have decreased numbers of hematopoietic progenitors when grown in culture. Transfer of the normal Fanconi anemia cDNA into cells from patients corrects the laboratory abnormalities, suggesting that gene transfer may prevent or reverse the bone marrow failure. Advances in gene transfer into human hematopoietic cells make this approach seem feasible. However, decreased numbers of stem cell targets may represent a significant obstacle. In addition, new insights on potential toxicities related to gene transfer have heightened a cautious approach. Fanconi anemia represents a prototype disorder for gene therapy and highlights the difficulties in adapting this technology to human disease.

AB - Fanconi anemia is a hereditary syndrome of bone marrow failure, congenital anomalies, and a predisposition to malignancy. Most patients die from bone marrow failure. Cells from patients display a heightened sensitivity to DNA cross-linking agents with increased chromosomal breakage and increased cytotoxicity. Bone marrow from patients with Fanconi anemia have decreased numbers of hematopoietic progenitors when grown in culture. Transfer of the normal Fanconi anemia cDNA into cells from patients corrects the laboratory abnormalities, suggesting that gene transfer may prevent or reverse the bone marrow failure. Advances in gene transfer into human hematopoietic cells make this approach seem feasible. However, decreased numbers of stem cell targets may represent a significant obstacle. In addition, new insights on potential toxicities related to gene transfer have heightened a cautious approach. Fanconi anemia represents a prototype disorder for gene therapy and highlights the difficulties in adapting this technology to human disease.

UR - http://www.scopus.com/inward/record.url?scp=0141921619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141921619&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 335

EP - 340

JO - Current hematology reports

JF - Current hematology reports

SN - 1540-3408

IS - 4

ER -